Equity · Healthcare
FLGT
NASDAQFulgent Genetics (FLGT)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 518.5M USD
- Revenue, year to Dec 2025
- 322.7M USD
- 52-week range
- 13.80 USD – 31 USD
- Avg volume
- 69.9K
as of Aug 14, 2026
Have Fulgent Genetics (FLGT) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Fulgent Genetics insiders reported 4 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 26 Oct 2025, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 2 Sep 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Sep 2026 | Xie JianPresident and COO | Sell | 2,127 | 42K USD |
| 02 Sep 2026 | Gao HanlinChief Scientific Officer | Sell | 1,673 | 33K USD |
| 27 Aug 2026 | Xie JianPresident and COO | Sell | 1,193 | 24K USD |
| 27 Aug 2026 | Gao HanlinChief Scientific Officer | Sell | 939 | 19K USD |
| Sold | 4 open-market sales | 5,932 | $117K |
7 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 26 Oct 2026 | Kim PaulCFO and Treasurer | Tax withheld | 2,748 | 56K USD |
| 26 Oct 2026 | Xie JianPresident and COO | Tax withheld | 4,361 | 88K USD |
| 26 Oct 2026 | Gao HanlinChief Scientific Officer | Tax withheld | 1,645 | 33K USD |
| 01 Sep 2026 | Hsieh MingChief Executive Officer | Tax withheld | 4,392 | 86K USD |
| 01 Sep 2026 | Kim PaulCFO and Treasurer | Tax withheld | 2,087 | 41K USD |
| 26 Aug 2026 | Hsieh MingChief Executive Officer | Tax withheld | 2,949 | 58K USD |
| 26 Aug 2026 | Kim PaulCFO and Treasurer | Tax withheld | 1,168 | 23K USD |
Which funds hold Fulgent Genetics (FLGT)?
8 of the 45 institutional funds we track reported a Fulgent Genetics position for the quarter ended 30 Jun 2026 — a combined 33.0M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Held (±25%) | 400,986 | 8.2M USD | +24.5% |
| Millennium Management | Held (±25%) | 320,910 | 6.6M USD | −20.1% |
| D. E. Shaw & Co. | Trimmed | 292,006 | 6.0M USD | −40.0% |
| Point72 Asset Management | New position | 211,708 | 4.3M USD | |
| Citadel Advisors | Added | 174,180 | 3.6M USD | +229.0% |
| Tudor Investment Corp | Added | 81,727 | 1.7M USD | +27.5% |
| AQR Capital Management | Added | 69,453 | 1.4M USD | +135.9% |
| Balyasny Asset Management | New position | 55,078 | 1.1M USD | |
| Renaissance Technologies | Exited |
What has been filed or recorded for Fulgent Genetics (FLGT)?
The filings we hold for Fulgent Genetics, newest first: 2 fails-to-deliver days, 3 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 09 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 09 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,691 shares | 35K USD notional · 0.006% of shares out |
| 01 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,982 shares | 88K USD notional · 0.014% of shares out |
| 30 Sep 2026 | Financials | Total assets | 1.1B USD | at period end |
| 30 Sep 2026 | Financials | Total equity | 990.5M USD | at period end |
| 31 Dec 2025 | Financials | Revenue | 322.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −60.5M USD | fiscal year |
| 31 Dec 2018 | Annual report | FY 2018 reported | EPS −0.11 USD | |
| 30 Sep 2018 | Quarterly earnings | Q3 2018 reported | Revenue $6M | |
| 30 Jun 2018 | Quarterly earnings | Q2 2018 reported | Revenue $5M | |
| 31 Mar 2018 | Quarterly earnings | Q1 2018 reported | Revenue $5M | |
| 31 Dec 2017 | Annual report | FY 2017 reported | EPS −0.09 USD | Revenue $4M |
What do people ask about Fulgent Genetics (FLGT)?
What did Fulgent Genetics shares close at?18.56
Fulgent Genetics closed at 18.56 USD on 14 Aug 2026, down 0.64% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Fulgent Genetics’ market cap?518.5M
Fulgent Genetics is worth 518.5M USD by market value as of 14 Aug 2026, which is the share price times the shares on issue from its SEC filings.
What is Fulgent Genetics’ revenue?322.7M
Fulgent Genetics reported revenue of 322.7M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Fulgent Genetics insiders bought or sold shares recently?4 sales
In the 90 days to 10 Nov 2026, Fulgent Genetics insiders reported 4 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 26 Oct 2025, show no open-market purchase. A further 7 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Fulgent Genetics?8 of 45
8 of the 45 funds we track reported a Fulgent Genetics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Millennium Management and D. E. Shaw & Co. See Funds
When did Fulgent Genetics last report earnings?−0.11
Fulgent Genetics last reported earnings on 31 Dec 2018 for FY 2018, with EPS of −0.11 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings